Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer (Locally Advanced or Metas...
Phase Not Applicable
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, single-center, open-label, real-world observational study plans to enroll 10-15 patients with advanced (Stage IV) breast cancer who have failed multiple prior therapies \[aged 18-75, Eastern Cooperative Oncology Group Performance Status Clinical Classification(ECOG) 0-2, with measurable and injectable lesions\]. It aims to preliminarily evaluate the antitumor activity, safety, and immune-microenvironment modulation of intratumoral H101(Recombinant Human Adenovirus Type 5 Injection) oncolytic virus combined with immune checkpoint inhibitors (ICIs) in real-world practice. The regimen is determined by physicians based on clinical status and multidisciplinary input, but follows a standardized framework: 2- to 3-week cycles; H101 injected on day 1 (dose stratified by lesion size), with ICI infusion started 7±2 days later, for 4 planned cycles. Paired tumor biopsies (when feasible) and peripheral blood are collected at baseline and after 4 cycles for single-cell RNA sequencing and immune profiling, focusing on changes in T lymphocyte (T), Natural Killer cell (NK), dendritic, and macrophage subsets and correlating with clinical outcomes. Primary endpoints include adverse events (Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0(CTCAE v5.0)), objective response and local control rates (Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST 1.1)), 4-cycle completion, and toxicity-related discontinuation. Secondary endpoints include disease control rate, progression-free survival (Kaplan-Meier), and dynamic immune changes. First radiological assessment occurs at 6-8 weeks post-treatment, then every 3 months until progression, loss to follow-up, or 1 year. If re-biopsy is unsafe, only peripheral blood may be collected without protocol violation. Comprehensive follow-up, data confidentiality, and missing-data handling are in place to ensure scientific validity and participant protection.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Incidence of Adverse Events (From first dose of study treatment through 30 days after the last dose (up to approximately 8-12 weeks))
  • Objective Response Rate (6-8 weeks after the end of treatment (after completion of 4 treatment cycles))
  • Local Control Rate (Baseline and every 3 months up to 1 year after the end of treatment)
  • Treatment Feasibility (During the treatment period (up to 4 cycles, each cycle 2-3 weeks))
  • Tolerability of the study drug in participants (From first dose of study treatment through 30 days after the last dose (up to approximately 8-12 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-09-09
Completion: 2028-02-29
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jie Yuan,MD
Contact Information
Study Contact:
Jie Yuan, Doctoral degree
+86 13016007353
candlewjy@163.com
Jie Yuan
0757-82778323
Jie Yuan, Doctoral degree
+86 13016007353
candlewjy@163.com
Foshan Fosun Chancheng Hospital
Interventions
N/A
Study Locations (1 sites)
Foshan Fosun Chancheng Hospital, Guangdong, Foshan China
Eligibility Criteria
Inclusion Criteria: * Age 18 to 75 years, both genders; * Pathologically confirmed breast cancer (Stage IV); * Disease progression after at least one line of standard systemic therapy; * ECOG performance status 0-2; * Intolerant to or refusal of standard chemotherapy; * At least one radiologically measurable lesion per RECIST 1.1 criteria; * At least one lesion amenable to puncture/injection (i.e., accessible for intratumoral injection); * Estimated life expectancy ≥3 months; * Adequate major organ function as defined by the following laboratory values:Absolute neutrophil count (ANC) ≥1.5×10⁹/L,Platelet count (PLT) ≥100×10⁹/L,Hemoglobin (Hb) ≥90 g/L,Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤2.5× upper limit of normal (ULN),Serum creatinine (Cr) ≤1.5× ULN; * Signed informed consent form; * Agreement to provide tumor tissue samples and peripheral blood samples before and after treatment for research purposes.。 Exclusion Criteria: * Known allergy to H101 formulation, PD-1 inhibitors, or any of their excipients ; * Lymphocyte count \<0.5×10⁹/L; * Severe infection, active infection (particularly HBV, HCV, HIV), or severely immunocompromised status; * Presence of lesions that cannot be safely punctured/injected; * Prior treatment with PD-1/PD-L1 inhibitors with grade ≥3 immune-related adverse events that have not resolved; * Concurrent active malignancy other than breast cancer (except for those cured for \>5 years with no evidence of recurrence); * Uncontrolled brain metastases; * Pregnant or breastfeeding wome; * Psychiatric disorders, cognitive impairment, or poor compliance that may interfere with study participation and completion; * Severe cardiac, hepatic, or renal failure; * Long-term immunosuppressive therapy; * Uncontrolled active autoimmune disease.
Conditions Breast Cancer
Phase NA
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The new technology of endoscopic-assisted system, as an emerging technology, has shown certain application prospects in breast surgery. However, the new technology of endoscopic-assisted mastectomy and immediate breast reconstruction in China in the treatment of breast cancer is still in the exploratory stage and needs to be further improved. This prospective, single-center, double-arm clinical study was conducted to use the endoscopic-assisted system and evaluate the effectiveness and safety of the mastectomy combined with immediate breast reconstruction in breast cancer.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Procedure: endoscopic-assisted mastectomy and immediate breast reconstruction — endoscopic-assisted mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer
  • Procedure: mastectomy and immediate breast reconstruction — conventional mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer

Primary Outcomes

  • Local recurrence free survival rate (LRFS) (3 years)
  • Regional recurrence free survival rate (RRFS) (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2028-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
Qiang Ding, Professor
13951731373
dingqiang@njmu.edu.cn
Qiang Ding, Professor
+8613951731373
dingqiang@njmu.edu.cn
The First Affiliated Hospital with Nanjing Medical University
Interventions
  • Procedure: endoscopic-assisted mastectomy and immediate breast reconstruction — endoscopic-assisted mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer
  • Procedure: mastectomy and immediate breast reconstruction — conventional mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer
Study Locations (1 sites)
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu 210009 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients, aged 18-75 years old; The pregnancy test (-) and reliable contraceptive methods are required for premenopausal and perimenopausal patients; 2. Patients with the diagnosed breast cancer confirmed by core needle biopsy and unilateral operation was performed; Breast cancer patients with tumor node metastasis stage 0-III according to the 8th edition of the American Joint Commission on Cancer; Preoperative clinical examination or imaging evaluation shows that the distance between the tumor and the Nipple Areolar Complex (NAC) is more than 1cm. The tumor has a diameter of 2-3 cm and can be located in any quadrant or reduced to 3 cm through preoperative neoadjuvant chemotherapy. The distance between the lesion and the skin should be at least 8-10 mm; 3. There is no clinical or imaging evidence to prove that the tumor has invaded the skin, chest wall, or nipple areola complex; 4. There are indications for breast preservation, but the patient has a strong desire for reconstruction and is unwilling to undergo breast preservation surgery; 5. Preventive mastectomy (BRCA1/2 malignant mutation with obvious family history of breast cancer and other high-risk groups); 6. Preoperative clinical manifestations and imaging data showed no distant metastasis; 7. No history of breast cancer or other serious underlying diseases in the past; 8. Karnofsky performance status score ≥ 70; 9. Eastern Cooperative Oncology Group score ≤ 2 ; 10. The surgical procedure includes endoscopic-assisted/conventional mastectomy, sentinel lymph node biopsy/axillary lymph node dissection and immediate breast reconstruction; 11. Participants are able to understand the research process, voluntarily join the study, sign informed consent forms, have good compliance, and cooperate with follow-up; 12. No swallowing difficulties; No shoulder joint movement disorders; 13. Complete clinical data. Exclusion Criteria: 1. Male breast cancer or inflammatory breast cancer; 2. Metastatic breast cancer (stage IV); Tumor invasion of the skin, pectoralis major muscle, or NAC; 3. The clinical data is basically incomplete; 4. Previously received chemotherapy in an external hospital or has undergone tumor resection in an external hospital; 5. Bilateral breast cancer surgery; 6. Other surgical methods; 7. Preoperative distant metastasis or supraclavicular lymph node dissection; 8. Complicated with other malignant tumors or had malignant tumors other than breast cancer in recent 5 years; 9. The serious disease of non malignant tumors combined will affect the patient's compliance or put the patient in a dangerous state; 10. Dementia, intellectual disability, or any mental illness that hinders understanding of informed consent forms.
Conditions HER2-Negative Breast Cancer
Phase PHASE2
Enrollment 39
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Angiogenesis inhibition represents a significant therapeutic target in breast cancer; however, despite its theoretical feasibility, progress in advanced breast cancer has been slow. Currently, there is a lack of prospective data supporting the selection of tyrosine kinase inhibitors (TKIs) in combination with local therapy. This phase II study aims to evaluate the efficacy and safety of stereotactic radiotherapy (SRT) or whole-brain radiotherapy (WBRT) combined with anlotinib in patients with HER2-negative advanced breast cancer and brain metastases.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor — Based on the size, location and number of brain metastases, an appropriate radiotherapy plan is given. Arloxitin can be used starting from the 1st day after radiotherapy to within 1 week. Arloxitin 12 mg, qd (it is recommended to take it before meals and take the medicine at the same time every day), take orally continuously for 2 weeks and then stop for 1 week. A 21-day period constitutes one treatment cycle. During the medication period, if there is a missed dose, if the time from the missed dose to the next dose is less than 12 hours, no additional dose will be given.

Primary Outcomes

  • Central nervous system progression-free survival (CNS-PFS) rate (12months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-02-10
Completion: 2028-06-01
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 39 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
Chi Zhang
025-83714511
jsphkj@163.com
MingHui Zhao
025-68306360
The First Affiliated Hospital of Nanjing Medical University
Interventions
  • Drug: Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor — Based on the size, location and number of brain metastases, an appropriate radiotherapy plan is given. Arloxitin can be used starting from the 1st day after radiotherapy to within 1 week. Arloxitin 12 mg, qd (it is recommended to take it before meals and take the medicine at the same time every day), take orally continuously for 2 weeks and then stop for 1 week. A 21-day period constitutes one treatment cycle. During the medication period, if there is a missed dose, if the time from the missed dose to the next dose is less than 12 hours, no additional dose will be given.
Study Locations (1 sites)
The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Eligibility Criteria
Inclusion Criteria: * Female patients aged 18 to 70 years (calculated on the date of informed consent signing). * Karnofsky Performance Status (KPS) score ≥ 70, or KPS = 60 primarily attributable to neurological symptoms. * HER2-negative status confirmed by pathology from Jiangsu Provincial Hospital's Pathology Department. HER2 immunohistochemistry (IHC) must be (-) or (1+). Patients with HER2 IHC (2+) must have a negative result on confirmatory fluorescence in situ hybridization (FISH) testing. * Presence of brain metastases confirmed by contrast-enhanced cranial MRI prior to enrollment. At least one measurable intracranial lesion is required according to RANO-BM criteria. * If prior anti-tumor therapy (excluding treatments specifically targeting intracranial metastases) has been administered, a washout period of at least 2 weeks is required. Any prior treatment-related toxicities must have resolved to ≤ Grade 2 (CTCAE v3.0; excluding alopecia and hematological toxicities). Concurrent use of bisphosphonates, mannitol, corticosteroids, etc., is permitted during the study. Corticosteroid dosage must have been stable for at least one week prior to enrollment (e.g., dexamethasone ≤ 16 mg/day or equivalent). * Life expectancy of at least 3 months. * Adequate organ and hematological function, meeting the following criteria: 1. Hematology (without transfusion or growth factor support within 14 days): * Hemoglobin (Hb) ≥ 80 g/L. * Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L. * Platelet count (PLT) ≥ 50 × 10⁹/L. 2. Biochemistry: * Total bilirubin (TBIL) \< 1.5 × upper limit of normal (ULN), or ≤ 3 × ULN in patients with liver metastases. * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN, or ≤ 5 × ULN in patients with liver metastases. * Serum creatinine (Cr) ≤ 1.5 × ULN or calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula). * Magnesium ≥ lower limit of normal (LLN). * Women of childbearing potential must be surgically sterile, postmenopausal, or agree to use highly effective contraception (e.g., oral contraceptives, intrauterine device, sexual abstinence, or barrier methods with spermicide) during the study and for 6 months after the final dose. A negative serum pregnancy test within 7 days prior to enrollment is required for all non-sterile, premenopausal women (positive results must be ruled out as false-positive by ultrasound). Patients must not be breastfeeding. * Voluntary participation with written informed consent. Exclusion Criteria: * Patients with extensive leptomeningeal metastasis or hemorrhagic brain metastases. * Patients with uncontrolled seizures. * Patients with any other severe and/or poorly controlled concurrent medical condition that, in the investigator's judgment, prohibits their participation in this clinical study, including but not limited to: 1. Factors significantly affecting oral drug intake (e.g., inability to swallow, chronic diarrhea, intestinal obstruction). 2. Known hypersensitivity to anlotinib or any component of the investigational product. 3. History of immunodeficiency, including HIV positivity, other acquired or congenital immunodeficiency diseases, or history of organ transplantation. 4. Clinically significant cardiovascular disease (defined as: unstable angina, symptomatic congestive heart failure of New York Heart Association \[NYHA\] Class ≥ II, uncontrolled severe arrhythmia), or myocardial infarction within 6 months prior to enrollment. 5. Active or uncontrolled infection requiring systemic treatment within 2 weeks prior to enrollment (excluding simple urinary tract infections or upper respiratory tract infections). 6. History of concurrent other malignancies, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix. * Patients who are pregnant, breastfeeding, or planning to become pregnant during the treatment period or within 6 months after treatment completion. * Patients (including female patients and/or their male partners) unwilling to use effective contraception during the treatment period and for 6 months after treatment completion. * Patients ineligible for contrast-enhanced MRI examinations. * Patients who have previously received anti-angiogenic TKI therapy and experienced intracranial progression (Note: Patients who received prior anti-angiogenic TKI therapy without subsequent disease progression are eligible. Patients previously treated with anti-angiogenic macromolecular agents, such as bevacizumab, are eligible). * Patients with a history of other malignancies within the past 5 years or concurrent other malignancies, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix. (Note: This appears to be a duplicate of criterion 3f. In standard protocols, it is typically listed once.). * Patients unwilling or unable to comply with scheduled follow-up as required by the study protocol. * Any other condition assessed by the investigator that may affect the patient's compliance with the protocol or the evaluation of study endpoints, rendering the patient unsuitable for study participation.
Conditions Cognitive Dysfunction
Phase Not Applicable
Enrollment 5000
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this observational study is to evaluate the accuracy and feasibility of an artificial intelligence-based multimodal cognitive screening system in early identification of diabetes-related mild cognitive impairment (MCI) among type 2 diabetes mellitus (T2DM) patients through a 3-5 year follow-up. It also aims to analyze the correlation between diabetic metabolic indicators (such as glycemic variability and HbA1c levels) and cognitive function changes, thereby determining the value of this intelligent screening system in early detection and intervention of cognitive impairment in T2DM patients, which constitutes the key focus of this research.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: follow-up observation — In this study, no additional interventions were administered to any enrolled participants; only 3-5 years of follow-up observation were conducted, with cognitive status data collected at both baseline and endpoint.

Primary Outcomes

  • Early Identification Accuracy of the AI System (From enrollment to the end of follow-up for 3-5 years)
  • Cognitive Deterioration Rate (From enrollment to the end of follow-up for 3-5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-22
Completion: 2028-12-30
Eligibility
Age: 40 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tongji Hospital
Contact Information
Study Contact:
Prof. Yang, Doctor
86-18827397697
yangyantj@qq.com
Maorong Wang
+8613986865499
snowwhite734@163.com
Minda Hospital Affiliated to Hubei Minzu University
Ting Ding
+8615377133959
54431050@qq.com
Huanggang Central Hospital
Interventions
  • Other: follow-up observation — In this study, no additional interventions were administered to any enrolled participants; only 3-5 years of follow-up observation were conducted, with cognitive status data collected at both baseline and endpoint.
Study Locations (21 sites)
Minda Hospital Affiliated to Hubei Minzu University, Enshi, Hubei China
Huanggang Central Hospital, Huanggang, Hubei China
Huangshi Central Hospital, Huangshi, Hubei China
Jingzhou Central Hospital, Jingzhou, Hubei China
Sinopharm Dongfeng General Hospital, Shiyan, Hubei China
Suizhou Central Hospital, Suizhou, Hubei China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030 China
China Resources & WISCO General Hospital, Wuhan, Hubei China
Hubei Provincial Hospital of Integrated Chinese & Western Medicine, Wuhan, Hubei China
Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei China
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria 1. Diagnosed with type 2 diabetes mellitus (T2DM). 2. Aged 40-75 years, with self-reported or informant-reported memory complaints. 3. Cognitive assessment scores consistent with either: * Cognitive Normal (CN) or * Mild Cognitive Impairment (MCI). 4. Preserved ability to perform basic activities of daily living (ADLs). 5. Memory-specific deficits only (e.g., partial forgetfulness), with intact other cognitive domains (e.g., reasoning, judgment, attention, and executive function). Exclusion Criteria: 1. Other types of diabetes (e.g., type 1 diabetes, gestational diabetes). 2. Education level \<6 years. 3. Metabolic disorders that may affect cognition, including: * Acute carbohydrate metabolism events within 3 months (e.g., severe hypoglycemia, diabetic ketoacidosis, hyperglycemic hyperosmolar state). * Hypothyroidism or other endocrine disorders. 4. Neurological/psychiatric conditions that may impair cognition: * History of head trauma, depression, anxiety, delirium, severe pulmonary/renal disease, heart failure, or malignancy. 5. Substance abuse (past 2 years), including nicotine/alcohol dependence. 6. Recent medication use (within 1 month): * Anti-Parkinsonian drugs, antiepileptics, sedatives/hypnotics. 7. Cognitive-enhancing drugs (e.g., donepezil, memantine). 8. Inability to complete AI screening or follow-up due to: * Speech/hearing/visual impairments or other disabilities
Conditions Type 2 Diabetes
Phase PHASE4
Enrollment 204
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Metformin — The dosage and dose frequency are maintained as they were before the screening.
  • Drug: Dapagliflozin/Pioglitazone — Dapagliflozin 10mg/Pioglitazone 30mg QD
  • Drug: Dapagliflozin/Sitagliptin — Dapagliflozin 10mg/Sitagliptin 100mg QD

Primary Outcomes

  • HbA1c (%) change at 24 weeks compared to the baseline (Visit 2) (From baseline to end of treatment at 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-06-11
Completion: 2026-10-01
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 204 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boryung Pharmaceutical Co., Ltd
Contact Information
Study Contact:
Oh
+82 2-708-8000
syoh@boryung.co.kr
Interventions
  • Drug: Metformin — The dosage and dose frequency are maintained as they were before the screening.
  • Drug: Dapagliflozin/Pioglitazone — Dapagliflozin 10mg/Pioglitazone 30mg QD
  • Drug: Dapagliflozin/Sitagliptin — Dapagliflozin 10mg/Sitagliptin 100mg QD
Study Locations (1 sites)
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho District 06591 South Korea
Eligibility Criteria
Inclusion Criteria: * Has voluntarily agreed to participate in this clinical trial. * Adults over 19 years of age * Diagnosed with type 2 diabetes Exclusion Criteria: * Has severe renal and liver disorders * Has type 1 diabetes * Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study * Those who are deemed ineligible to participate in the study by the investigator
Conditions Diabetes Mellitus
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Exhaled volatile organic compounds will be measured during daytime with the goal to identifying circadian variability. The study incudes three subgroups: people without diabetes, people with type 1 diabetes, and people with type 2 diabetes. A total of 60 people will be recruited for the study.

Design

Study type: Observational Observational model: Other Time perspective: Other

Interventions / Regimen

  • Other: Standardized meal — The participants will receive a standardized meal for breakfast

Primary Outcomes

  • VOC Patterns over time as gallery plots (During the study procedure (approximately 8 hours))
  • VOC Patterns over time as boxplots (During the study procedure (approximately 8 hours))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-08-07
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Bern
Collaborators: Insel Gruppe AG, University Hospital Bern, DCB Research AG
Principal Investigators:
  • Lilian Witthauer, Prof.Dr. (PRINCIPAL_INVESTIGATOR) - University of Bern
Contact Information
Study Contact:
Lilian Witthauer
+41 31 664 22 77
lilian.witthauer@unibe.ch
Witthauer Lilian, Prof.Dr.
+41 31 664 22 77
lilian.witthauer@unibe.ch
University of Bern
Witthauer Lilian, Prof.Dr.
University of Bern
Interventions
  • Other: Standardized meal — The participants will receive a standardized meal for breakfast
Study Locations (1 sites)
University of Bern, Bern, 3010 Switzerland
Eligibility Criteria
Inclusion criteria Subgroup 1: * Age 18 or older * HbA1c below 6.5% * Written informed consent Subgroup 2: * Age 18 or older * T1D (Type 1 diabetes) with MDI (multiple daily injection) or CSII (Continuous subcutaneous insulin infusion therapy) therapy \>1 year * Written informed consent Subgroup 3 * Age 18 or older * T2D (Type 2 diabetes) with oral antidiabetic medication or insulin therapy * Written informed consent Exclusion criteria * Pregnancy or breastfeeding * Smoking (last cigarette less than 6 months ago) * Any chronical lung and intestinal disease diagnosis (such as intestinal bowel disease (IBD); asthma; COPD (chronic obstructive pulmonary disease); lung cancer, …) * Coeliac disease * Lactose and fructose intolerance * Any acute disease diagnosis (such as viral or bacterial infection) * Drinking habit of more than four units of alcohol per day * Current inhaled medicines treatments * Antibiotic treatment in the previous 4 months
Conditions Type 2 Diabetes Mellitus, Gene Polymorph...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

In this study, investigators wanted to determine the effect of T2DM susceptibility gene mutations on self-expression. Participants (T2DM patients and controls) were recruited to identify genotypes and detect the levels of T2DM susceptibility genes expression in the fresh peripheral plasma. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were also collected to identify the expression differences of T2DM susceptibility genes under different genotypes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs — Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
  • Drug: Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs — The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection. In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.

Primary Outcomes

  • Detection of T2DM susceptibility gene expression in newly diagnosed T2DM patients (1 month after fresh sample collection)
  • Detection of T2DM susceptibility gene expression in controls (1 month after fresh sample collection)
  • Correlation between T2DM susceptibility gene expression and clinicopathological features (6 months after obtaining the clinicopathological results)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-01
Completion: 2028-01-31
Eligibility
Age: 25 Years – 70 Years
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Affiliated Hospital of Xuzhou Medical University
Contact Information
Study Contact:
Tao Wang, Ph.D
13815344640
misswt2011@126.com
Xiaoxing Yin, Ph.D
13605218523
yinxx@xzmc.edu.cn
Hongwei Ling, MD
18052268607
linghongwei@medmail.com.cn
China, Jiangsu, Department of Endocrinology
Interventions
  • Drug: Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs — Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
  • Drug: Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs — The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection. In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.
Study Locations (1 sites)
China, Jiangsu, Department of Endocrinology, Xuzhou, 221006 China
Eligibility Criteria
Inclusion Criteria: 1. no drug therapy; 25 to 70 years old; Hemoglobin A1c (HbA1c) 7%-12%; BMI 20-35 kg/m2; Stable body weight (≤10% change within 3 months)(For newly diagnosed patients with T2DM). 2. 25 to 60 years old; BMI 19-26 kg/m2; in good health, with no abnormalities of motor system, digestive system, respiratory system, urogenital system, blood system, circulatory system, nervous/mental system, endocrine system, etc(For healthy subjects). 3. 20-80 years old; surgical resection of part or all of the pancreas; pancreatic lesions confirmed by enhanced CT or magnetic resonance (MR) examination or confirmed by intraoperative and postoperative pathology(For the patients in general surgical). Exclusion Criteria: 1. had taken antidiabetic drugs; 2. had a history of pancreatic surgery; 3. Complicated with severe organ lesions; 4. Long-term use of drugs that affect pancreatic function.
Conditions Diabetic Neuropathy, Sarcopenia
Phase Not Applicable
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to evaluate the relation between diabetic neuropathy in type 2 diabetes mellitus patients and muscle mass

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Primary Outcomes

  • Relation between diabetic neuropathy and muscle mass (Day 1 Neurological examination and clinical physical performance tests for sarcopenia, 2 weeks later: nerve conduction studies for both lower limbs, the 3rd week: ultrasound assessment for thigh muscle thickness)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-30
Completion: 2026-06-15
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams University
Principal Investigators:
  • Rana A Al Hilaly, MD (STUDY_DIRECTOR) - Ain Shams University
Contact Information
Study Contact:
Wafaa M Mohamed Abd ElAzim, Masters degree
+201012932752
wafaa.mahmoud@med.asu.edu.eg
Wafaa M Mohamed Abd ElAzim, Masters
+201012932752
wafaa.mahmoud.@med.asu.edu.eg
Ain Shams university
Interventions
N/A
Study Locations (2 sites)
Ain Shams university, Cairo, Abbassia 00202 Egypt
Ain Shams university, Cairo, Abbassia 00202 Egypt
Eligibility Criteria
Inclusion Criteria: * The study group consisted of patients diagnosed with Type 2 diabetes mellitus aged ≥45 years old Exclusion Criteria: * Type 1 DM, gestational diabetes mellitus * Severe cardiopulmonary disease, significant/previous neurological disorder (e.g., ischemic stroke, Parkinson disease) causing difficulty during daily activities (e.g., walking), visual deficit, and psychiatric problem * Other neuropathy-associated factors such as: alcohol, nutrition, poisoning and drug addiction * Patients with renal diseases, malignancy and autoimmune diseases * Patients on long term use of Steroids
Conditions Type 1 Diabetes, Type 2 Diabetes
Phase NA
Enrollment 45
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

A prospective, randomized, single blind, two-arms, multicenter study. The study aims to assess the safety of a dosing-guided system (DGS) that provides direct advice on insulin dosing recommendations and diabetes management to individuals with diabetes using insulin or starting basal insulin therapy, guided by their continuous glucose monitoring (CGM). The study population will include up to 45 individuals with diabetes, distributed as follows: 15 with Type 1 diabetes (T1D) and 15 with Type 2 diabetes (T2D), both on MDI therapy and 15 with T2D using or starting to use basal insulin. The study will include a 2- to 4-week run-in period followed by a 6-week intervention period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Dosing Guidance System to be used with both time and amount of insulin as input — Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input
  • Device: Dosing Guidance System to be used with only time of insulin as input — any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input

Primary Outcomes

  • Sensor glucose percentage of time in hypoglycemia below 54 mg/dL (Aafter 6 weeks of intervention period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-08
Completion: 2026-05-25
Eligibility
Age: 6 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rabin Medical Center
Collaborators: DreaMed Diabetes
Principal Investigators:
  • Moshe Phillip, MD (PRINCIPAL_INVESTIGATOR) - Schneider Children's Medical Center
Contact Information
Study Contact:
Alona Hamou, Msc
972-545950277
alonah@clalit.org.il
Moshe Phillip, Prof
972-3-9253282
mosheph@clalit.org.il
Schneider Children Medical Center of Israel
Revital Nimri, MD
Schneider Children Medical Center of Israel
Interventions
  • Device: Dosing Guidance System to be used with both time and amount of insulin as input — Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input
  • Device: Dosing Guidance System to be used with only time of insulin as input — any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input
Study Locations (2 sites)
Schneider Children Medical Center of Israel, Petah Tikva, 49202 Israel
University Medical Center of Ljubljana, Ljubljana, Slovenia
Eligibility Criteria
Inclusion Criteria: * Documented T1D or T2D, for at least 6 months * Aged ≥ 6 years ≤ 75 years * HbA1c ≤ 11% * For Segment 1: Using basal-bolus MDI therapy, i.e. basal insulin and a bolus that is either: 1. Carbohydrate counting with carbohydrate ratio (CR) and correction factor (CF) 2. Fix dose for meal / meal estimation with CF * For Segment 2: Using or prescribed basal insulin * Participants using the following type of insulin as directed in the instructions for use: 1. Basal insulin: Glargine (including Rezvoglar, Semglee, Toujeo, Soliqua), Degludec (including Tresiba U-100, Tresiba U-200, Xultophy), Determir 2. Bolus insulin: regular insulin, rapid analogues (Insulin Aspart, Insulin Glulisine, Insulin Lispro) or ultra-rapid analogues (Fiasp, Lyumjev) * Participants willing to use FreesStyle Libre CGM according to manufacturer instructions, document insulin delivery, meals, and daily activities. * Participants have a smartphone compatible with study requirements. * Participants are willing and able to sign a written informed consent form to use their data. * Participants are willing to use the bolus calculator for insulin dosing (only for segment 1) Exclusion Criteria: 1. Concomitant diseases/treatment that influence metabolic control or any significant diseases/conditions including psychiatric disorders and substance abuse or drug or alcohol abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patients' safety. 2. Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic foot syndrome) or any secondary disease or complication of diabetes mellitus, such as: 1. Subject has unstable or rapidly progressive renal disease or has eGFR \< 45 or is receiving dialysis 2. Subject has active proliferative retinopathy 3. Active gastroparesis 3. Participation in any other interventional study 4. Female participant who is pregnant or planning to become pregnant within the planned study duration 5. Individuals who are using one of the following types of insulin: 1. Intermediate-acting insulin (NPH) 2. Mixed insulin like: i. Premix NPH/ Regular (e.g. Humalin 70/30, Novolog 70/30) ii. Premix analogs (e.g, Novolog mix 70/30, Hu,alog mix 75, 25, Humalog Mix 50/50) c. Inhale insulin (e.g. Afrezza) 6. Hypoglycemia unawareness 7. Individuals who are treated with intravenous (IV) insulin injections, or a combination of insulin injections and/or IV insulin and insulin pump therapy. 8. Individuals who have extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. 9. An episode of diabetic keto-acidosis within the month prior to study entry and/or severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrolment.
Conditions Healthy Participants, Obesity, Type 2 Di...
Phase PHASE1
Enrollment 114
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The main purposes of this study are: * to investigate the safety and tolerability of ACI-19764 when it is administered to healthy participants and participants with cardiovascular risk factors * to determine how quickly and to what extent ACI-19764 is absorbed, transported, metabolized, and excreted by the body (fasted and after a meal) * to determine the effect of ACI-19764 on specific markers in the blood that are part of the immune system The effects of ACI-19764 will be compared with the effects of a placebo. ACI-19764 is a brain-penetrant NLRP3 inhibitor. The study consists of 3 parts, Part A (SAD, single ascending dose) and Part B (MAD, multiple ascending doses) in healthy participants, and Part C (one multiple-dose level) in participants with cardiovascular risk factors. Participants in Part A will receive the study compound once, and participants in Part B and Part C will receive the study compound multiple times (daily over 14 and 28 days, respectively). Parts A and B will be divided into different groups of participants to test different doses of ACI-19764.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Placebo — Placebo capsules matching ACI-19764 capsules
  • Drug: ACI-19764 at dose A1 — ACI-19764 capsules at dose A1
  • Drug: ACI-19764 at dose A2 — ACI-19764 capsules at dose A2
  • Drug: ACI-19764 at dose A3 — ACI-19764 capsules at dose A3
  • Drug: ACI-19764 at dose A4 — ACI-19764 capsules at dose A4
  • Drug: ACI-19764 at dose A5 — ACI-19764 capsules at dose A5
  • Drug: ACI-19764 at dose A6 — ACI-19764 capsules at dose A6
  • Drug: ACI-19764 at dose B1 — ACI-19764 capsules at dose B1

Primary Outcomes

  • Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely related, possibly related or probably related) (From first study treatment administration up to the end of the safety follow-up (i.e. 21 to 24 days after Day 4 for study Part A, 21 to 24 days after Day 17 for study Part B, and 21 to 24 days after Day 29 for study Part C))
  • Vital signs: Change from baseline in blood pressure (From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29))
  • Vital signs: Change from baseline in respiratory rate (From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29))
  • Vital signs: Change from baseline in pulse rate (From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29))
  • Vital signs: Change from baseline in body temperature (From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29))
  • ECG: Change from baseline in heart rate (From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29))
  • ECG: Change from baseline in PR interval (From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29))
  • ECG: Change from baseline in QRS interval (From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-01-28
Completion: 2026-12
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 114 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AC Immune SA
Collaborators: ICON Clinical Research
Principal Investigators:
  • Principal Investigator (PRINCIPAL_INVESTIGATOR) - ICON plc
  • Clinical Lead (STUDY_DIRECTOR) - AC Immune SA
Contact Information
Study Contact:
AC Immune Clinical Lead
+41213459121
clinicaltrials@acimmune.com
Interventions
  • Drug: Placebo — Placebo capsules matching ACI-19764 capsules
  • Drug: ACI-19764 at dose A1 — ACI-19764 capsules at dose A1
  • Drug: ACI-19764 at dose A2 — ACI-19764 capsules at dose A2
  • Drug: ACI-19764 at dose A3 — ACI-19764 capsules at dose A3
  • Drug: ACI-19764 at dose A4 — ACI-19764 capsules at dose A4
Study Locations (1 sites)
ICON, Groningen, 9728 NZ Netherlands
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent in a language understandable to the participant prior to any study-mandated procedure. 2. Healthy male (Parts A and B) or female (Part B) aged between 18 and 65 years (inclusive) at screening or, male or female with cardiovascular risk factors between 18 and 75 years (inclusive) (Part C). 3. For Parts A and B: Body mass index of 18.0 to 29.9 kg/m2 (inclusive) at screening. 4. For Part C: Presence of either obesity (defined as a BMI of 30.0-42.0 kg/m2 inclusive) and/or existing diagnosis of well controlled type II diabetes (with HbA1c \>6.5% or 48 mmol/mol and ≤8.5% or 69 mmol/mol) (for participants with diabetes the BMI can range between 18.0-42.0 kg/m2 inclusive). 5. For Part C: serum CRP \>3.0 mg/L and \<10.0 mg/L at screening and reconfirmed prior first dosing. 6. Ability to communicate well with the investigator, and to understand and comply with the study requirements. 7. Systolic blood pressure (SBP) 90-140 mmHg, diastolic blood pressure (DBP) 45-90 mmHg, and pulse rate 40 to 100 beats per minute (bpm) (all inclusive), measured on either arm (same arm used for both screening and admission), after 5 min in the supine position at screening and admission. For Part C: SBP may be 90-160 mmHg, and DBP 45-100 mmHg (all inclusive). 8. 12-lead safety ECG: QT interval corrected for HR using Fridericia's formula (QTcF) \<450 ms for male participants and \<470 ms for female participants, QRS interval \<120 ms, PR interval \<220 ms, and HR 40 to 100 bpm (inclusive), and without clinically relevant abnormalities, measured after 5 min in the supine position at screening and admission. 9. For Part C: Estimated glomerular filtration rate (eGFR) \>60 mL/min/1.73 m2 10. Fertile male participants (defined as physiologically capable of conceiving a child according to the investigator's judgment) must agree to refrain from fathering a child and: * Be sexually abstinent with women of childbearing potential (WoCBP) or use condoms during sexual intercourse with WoCBP from (first) study treatment administration up to at least 90 days after (last) study treatment administration. Male participants must advise their WoCBP partners consistently to use a highly effective method of contraception with a failure rate of \<1% per year. * Do not donate sperm from (first) study treatment administration up to at least 90 days after (last) study treatment administration. 11. Parts B and C only: Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at admission and a follicle-stimulating hormone (FSH) test must be performed at screening. WoCBP must agree to consistently and correctly use (from screening, during the entire study, and for at least 30 days after the last study treatment administration) a highly effective method of contraception with a failure rate of \<1% per year, be sexually inactive, or have a vasectomized partner with a post-vasectomy semen analysis negative for sperm at least 6 months before screening. If a hormonal contraceptive is used, it must be initiated at least 1 month before the first study treatment administration and should be used in conjunction with barrier methods. WoCBP must agree to not donate eggs from screening until at least 30 days after the last study treatment administration. 12. Parts B and C only: WoNCBP must be postmenopausal or have documented previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, uterine agenesis. Exclusion Criteria: 1. Known hypersensitivity to any excipient of the ACI-19764 formulations. 2. Known clinically relevant hypersensitivity or allergy to any therapeutic treatment (including non-steroidal anti-inflammatory drugs \[NSAIDs\], or nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 \[NLRP3\] inhibitors), vaccines, cosmetics, natural rubber or latex and/or food. 3. Clinically relevant findings on the physical examination at screening or on Day -1. 4. Clinically relevant findings in clinical laboratory tests 5. Clinically relevant history or presence of rhythm disorders, congestive heart failure, or structural heart disease. 6. History or presence of clinically relevant surgical intervention which, in the opinion of the investigator, could potentially interfere with the safety/tolerability and/or absorption, distribution, metabolism, and excretion (ADME) of the study treatment. 7. History or presence of acute, ongoing, recurrent, or chronic clinically relevant diseases which, in the opinion of the investigator, could potentially interfere with the assessment of safety/tolerability and/or ADME of the study treatment. For Part C: obesity, well-controlled type 2 diabetes, well-controlled hypertension, hypercholesterolemia, and osteoarthritis are acceptable co-morbidities. 8. For Part C: occurrence of diabetic ketoacidosis within the last 3 months 9. History or current acute or chronic pulmonary pathology including but not limited to chronic obstructive pulmonary disease (COPD), asthma, and recurrent lung infections. 10. Lifetime history of suicide attempt (including active attempt, interrupted attempt or aborted attempt) or suicidal ideation in the past 6 months according to the C-SSRS at screening (Parts B and C only). 11. History of cancer within the past 5 years other than treated squamous cell carcinoma, basal cell carcinoma, and melanoma in situ, or in-situ prostate cancer, in-situ cervix carcinoma, or in-situ breast cancer which have been fully removed and are considered cured. 12. Previous unexplained history of recurrent pre-syncope or syncope with no clear provoking features or syncope in the context of medical investigations that is likely to complicate interpretation of the safety of the drug in the opinion of the Investigator. 13. Veins unsuitable for intravenous (i.v.) puncture on both arms. 14. Participation in a clinical study involving study treatment administration within 3 months (or within 5 half-lives before screening, whichever is longer) prior to (the first) study treatment administration or in more than 3 clinical studies within 1 year prior to (the first) study treatment administration. 15. History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening. 16. Consumption of \>14 units of alcohol per week (females) or \>21 units per week (males). 17. Excessive caffeine consumption. 18. Nicotine consumption from 3 months prior to (first) study treatment administration, checked at screening and on Day -1. 19. Loss (including donation) of 450 mL or more of blood or blood products within 2 months prior to (the first) study treatment administration. 20. Positive results from serum/urine drug or alcohol screen test at screening or on Day -1. 21. Positive hepatitis B and/or C serology results, except for vaccinated participants or those with past but resolved hepatitis, at screening. 22. Positive human immunodeficiency virus (HIV) serology results at screening. 23. Any circumstances or conditions which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. 24. Legal incapacity or limited legal capacity at screening. 25. Treatment or intended treatment with any prescribed medications within 2 weeks prior to (first) study treatment administration, except for contraceptives (including hormonal contraceptive devices) in female participants (Part B and C only), and/or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 1 week prior to (first) study treatment administration. Analgesia with paracetamol is acceptable (but not NSAIDs or aspirin \>75 mg per day), unless for the short-term treatment of post lumbar puncture (LP) headache. For Part C: prescribed and OTC (including v
Conditions Diabetes Mellitus, Type 2
Phase PHASE3
Enrollment 210
Locations 40 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: CagriSema — CagriSema will be administered s.c. once weekly.

Primary Outcomes

  • Number of treatment emergent adverse events (TEAEs) (From baseline (Week 0) to end of treatment (Week 16))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-09-16
Completion: 2027-07-21
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 210 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novo Nordisk A/S
Principal Investigators:
  • Clinical Transparency (dept. 2834) (STUDY_DIRECTOR) - Novo Nordisk A/S
Contact Information
Study Contact:
Novo Nordisk
(+1) 866-867-7178
clinicaltrials@novonordisk.com
Interventions
  • Drug: CagriSema — CagriSema will be administered s.c. once weekly.
Study Locations (40 sites)
Gilbert Center For Family Medicine, Gilbert, Arizona 85296 United States
Ark Clinical Research, Fountain Valley, California 92708 United States
Thrive Clinical Research Group, Glendora, California 91740 United States
Scripps Whittier Diabetes Inst, La Jolla, California 92037 United States
Downtown LA Res Ctr. Inc., Los Angeles, California 90017 United States
Valley Clinical Trials, Inc., Northridge, California 91325 United States
Dream Team Clinical Research, Pomona, California 91767 United States
Clinical Trials Research_Sacramento, Sacramento, California 95821 United States
Linda Vista Health Care Ctr, San Diego, California 92111 United States
Chase Medical Research LLC, Waterbury, Connecticut 06708 United States
Eligibility Criteria
Inclusion criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus (T2DM) greater than or equal to (≥) 180 days before screening. * Stable once-weekly dose ≥ 90 days before screening of branded s.c. semaglutide. Branded semaglutide s.c. includes Ozempic and Wegovy. Participants on compounded semaglutide are ineligible. * Not on treatment with oral antidiabetic drugs or on stable daily dose(s) ≥ 90 days before screening of any of the following antidiabetic drug(s) or combination regimen at effective or maximum tolerated dose (MTD) as judged by the investigator: metformin and/or sodiumglucose co-transporter-2 (SGLT2) inhibitor. * Glycated haemoglobin (HbA1c) 6.5-10.5 percentage (%) (48-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening. * Body mass index (BMI) ≥ 25 kilograms per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening. Exclusion criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method from screening. * Renal impairment with estimated glomerular filtration rate (eGFR) less than (\<) 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening. * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * A self-reported change in body weight \> 5% within 90 days before screening irrespective of medical records. * Use of personal continuous glucose monitoring (CGM) devices. Participants currently using personal CGM devices must discontinue use prior to screening and throughout study participation.
Conditions Asthma
Phase PHASE2
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Biological: CM512 injection — subcutaneous injection
  • Drug: Placebo — subcutaneous injection

Primary Outcomes

  • Change from the baseline in Forced Expiratory Volume in one second (FEV1) (Up to week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-08-19
Completion: 2027-07-21
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Keymed Biosciences Co.Ltd
Principal Investigators:
  • Ruchong Chen (PRINCIPAL_INVESTIGATOR) - The First Clinical Hospital of Guangzhou Medical University
Contact Information
Study Contact:
Qian Jia
028-88610620
qianjia@keymedbio.com
Ruchong Chen
13710723826
chen_rch@163.com
The First Clinical Hospital of Guangzhou Medical University
Interventions
  • Biological: CM512 injection — subcutaneous injection
  • Drug: Placebo — subcutaneous injection
Study Locations (1 sites)
The First Clinical Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
Eligibility Criteria
Inclusion Criteria: * Able to understand and comply with procedures of the protocol, and voluntarily sign the Informed Consent Form. * Age ≥ 18 years old and ≤ 75 years old. * Body mass index (BMI) ≥ 18.0 kg/(m\*m). * Documented treatment with medium to high dose Inhaled Corticosteroids (ICS) in combination with asthma controller medication for at least 3 months with a stable dose ≥1 month prior to Visit 1. * Documented history of at least 1 severe asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS. * Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5 Exclusion Criteria: * Women of childbearing potential have a positive pregnancy test result during the screening period; women who are pregnant or lactating. * With a history of drug abuse within the past 5 years before screening visit. * Allergic or intolerant to CM512 injection or placebo components, or with a history of severe drug allergies or anaphylactic shock. * With any medical or non-medical conditions that are not suitable for participation in this study by investigators.